medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 4

<< Back Next >>

Med Int Mex 2018; 34 (4)

GLP-1 agonists plus SGLT2 inhibitors. Additive cardioprotective effects?

Matta-Herrera GJ, Ballestas-Alarcón LM, Ramírez-Rincón A

Language: Spanish
References: 95
Page: 601-613
PDF size: 415.00 Kb.


ABSTRACT

In South America, Colombia is secondly with number of diagnosed patients with diabetes mellitus (DM) and probably non-diagnostic patients. It has been calculated in Colombia 2 million people with diabetes mellitus, with a prevalence of 9.6% and it is the fifth position of causes of death and within the 10 causes that motivate the search for help. The new therapies with glucagon-like-1 receptors agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2i) have been shown individually and through different mechanisms of action impact on the metabolic control and other variables such as blood pressure, lipid profile, weight, renal and cardiovascular protection. Type 2 diabetes mellitus treatment guides recommend for patients with dual therapy who continue HA1c out of goals, consider triple therapy if the patient has not achieved the goals after three months. A systematic search was made that included search engines such as Pubmed, Embase and Cochrane, resulting in 12 articles. More clinical studies should be done with the combination of GLP-1 RAs and SGLT2i in the context of patients with type 2 diabetes mellitus with poor metabolic control despite dual and triple therapies.


REFERENCES

  1. International Diabetes Federation. The IDF Diabetes Atlas. 6th ed. Brussels: International Diabetes Federation, 2013.

  2. Vargas-Uricoechea y col. Epidemiología de la diabetes mellitus en Sudamérica: la experiencia de Colombia. Clin Invest Arterioscl 2016;28:245-56.

  3. Acuña-Merchán L. Situación de la enfermedad renal en Colombia 2014. Cuenta de alto costo Fondo Colombiano de Enfermedades de Alto Costo (2015).

  4. Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, et al; CARMELA Study Investigators. CARMELA: Assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008;21:58-65.

  5. Aschner P. Epidemiología de la diabetes en Colombia. Avances Diabetes 2010;26:95-100.

  6. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther 2012;14(1):S68-S74.

  7. United Kingdom Prospective Diabetes Study Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-53.

  8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-89.

  9. Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay et al. Consensus Statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 Diabetes Management algorithm 2017. Endocrine Practice 2017;23(No. 2) February.

  10. Goldenberg RM, Verma S, Perkins BA, Gilbert JD, Zinman CM. Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the yin and yang of glucagon? Can J Diabetes 2018;41:6-9.

  11. American Diabetes Association. Standards of medical care in diabetes 2017. J Clin Appl Res Educ Diabetes Care 2017;40(Supplement 1) January.

  12. Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab 2010;95:e234-9.

  13. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-83.

  14. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.

  15. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88(1):220-4.

  16. Mentlein R. Gallwitz B. Schmidt WE. Dipeptidyl peptidase IV hidrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsable for their degradation in human serum. Eur J Biochem FEBS 1993;214(3):829-35.

  17. Chen K, Yu X, Murao K, Imachi H, Li J, Muraoka T, et al Exendin- 4 regulate Glut 2 expression via the CaMKK/CaMKIV pathway in a pancreatic beta-cell line. Metabolism: Clin Exp 2011; 60(4):579-85.

  18. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.

  19. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-5.

  20. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42.

  21. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab 2013;28:262-74.

  22. Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 2013;23:4011-8.

  23. Perez López G, González Albarran O, Cano Megias M. Sodium-glocose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus. Nefrología 2010;30(6):618-25.

  24. Balderas I. (2016) Diabetes, obesidad y syndrome metabolico. Un abordaje multidisciplinario (1a ed.). Recuperado de http://www.manualmoderno.com

  25. Rossetti L, Smith D, Shulman GI, Papachristou D, de Fronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-5.

  26. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012 Jan;14(1):5e14.

  27. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005 Dec;54(12):3427e34.

  28. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-17.

  29. Gorgojo-Martínez JJ. Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad. Hipertens Riesgo Vasc 2014;31(2):45-57.

  30. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014;8:1335-80.

  31. McFarlane SI. Insulin therapy and type 2 diabetes: management of weight gain. J Clin Hypertens (Greenwich) 2009;11(10):601‐7.

  32. Biesenbach G, Raml A, Alsaraji N. Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI. Diab Obes Metab 2006; 8(6):669-73.

  33. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-50.

  34. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394-402.

  35. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122(1):4-12.

  36. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995;38(3):337‐43.

  37. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85(11):4053‐9.

  38. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987;36(3):274-83.

  39. Abdul Ghani M, DeFronzo RA. Fasting hyperglycemia impairs glucose but not insulin mediated suppression of glucagon secretion. J Clin Endocrinol Metabl 2007;92(5):1778‐84.

  40. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.

  41. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-14.

  42. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.

  43. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, et al, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.

  44. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, et al, SUSTAIN-6 investigator. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.

  45. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor diabetes Division University of Texas Health Science Center San Antonio, TX. doi: 10.1111/ dom.12982

  46. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95:513-548.

  47. Bunck MC, Corner A, Eliasson B, Heine RJ, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041- 2047.

  48. Chang AM, Jakobsen G, Sturis J, Smith MJ, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791.

  49. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose- Rafizadeh C. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995;136(11):4910-7.

  50. Murao K, Li J, Imachi H, Muraoka T, et al. Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line. Diab Obes Metab 2009;11(10):939-46.

  51. Park JH, Kim SJ, Park SH, Son DG, Bae JH, Kim HK, et al. Glucagon-like peptide-1 enhances glucokinase activity in pancreatic beta-cells through the association of Epac2 with Rim2 and Rab3A. Endocrinology 2012;153(2):574-82.

  52. Fehmann HC, Habener JF. Insulinotropic hormone glucagon- like peptide- I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC -1 cells. Endocrinology 1992;130(1):159-66.

  53. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, et al Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-852.

  54. Van Bloemendaal L, RG IJ, Ten Kulve JS, Barkhof F, et al. GLP- 1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014;63:4186-4196.

  55. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI: Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014;37:666-670.

  56. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide- 1 receptor agonists--available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011;13:394-407.

  57. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017;13:11-26.

  58. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodiumglucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Renal Physiol 2015;309:F889- 900.

  59. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-630.

  60. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730-1735.

  61. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A metaanalysis comparing clinical effects of short-or long-acting GPL-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetes patients. Diabetes Obes Metab 2017;19:216-227.

  62. Shwartz S, Eptein S, Corkey B. The time is right for a new classification system for diabetes: Rationale and implications of the beta cell centric classification schema. Diabetes Care 2016;39, February.

  63. Wang L, Li P, Tang Z, Yan Z, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: Compared evaluation of liraglutide and saxagliptin treatment. Scientific Reports 2016;6:33251.

  64. Cefalu WT, Leiter LA, Yoon KH, Arias P, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomized, doubleblind, phase 3 non-inferiority trial. Lancet 2013;382:941-50.

  65. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, et al, Investigators E-RO: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334.

  66. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, et al. Renal hemodynamic effect of sodium- glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597.

  67. Mann JF, Frandsen KB, Daniels G, Kristensen P, et al. Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER Trial. J Am Soc Nephrol (Abstract supplement) 2016;27:1B.

  68. Bolinder J, Ljunggren O, Kullberg J, Johansson L, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-1031.

  69. Jendle J, Nauck MA, Matthews DR, Frid A, et al; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diab Obes Metab 2009;11:1163-1172.

  70. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011;31:1285-1297.

  71. Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non- alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31:23-31.

  72. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.

  73. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose- regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853-862.

  74. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-35.

  75. Koska J, Sands M, Burciu C, D’Souza KM, et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: Evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 2015;64:624-2635.

  76. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week’s treatment with the long acting glucagon‐like peptide 1 derivative liraglutide (NN2211) markedly improves 24h glycemia and alpha and betacell function and reduces endogenous glucose reléase in patients with type 2 diabetes. Diabetes 2004;53(5):1187‐94.

  77. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon‐like peptide‐1 analog liraglutide on beta cell function in normal living conditions. Diabetes Care 2007;30(8):2032‐3.

  78. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Hormone Metab Res 2006;38(12):838-44.

  79. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic betacell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37(12):3270-8.

  80. Xu G, Stoffers DA, Habener JF, Bonner-Weir S Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48(12):2270-6.

  81. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates Beta cell apoptosis. J Biol Chem 2003;278 (1):471-8.

  82. Merovci A, Mari A, Solis C, Xiong J, Daniele G, Chavez- Velazquez A, Tripathy D, Urban McCarthy S, Abdul-Ghani M, DeFronzo RA. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab 2015;100:1927-1932.

  83. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, et al, group Ctc. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2016;18:82-91.

  84. Nilwala KG, Jayasinghe U, Greener VJ, Deher MD. Combining sglt2 inhibitor and glp-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes. Br J Diab 2016;16:138-139.

  85. Jensterle M, Pirs B, Goricar K, Dolzan V, Janez A. Genetic variation in GLP1 receptor is associated with interindividual differences in weight lowering potential of liraglutide in obese women with PCOS. 17th European Congress of Endocrinology, Endocrine Abstracts, 2015. http://dx.doi. org/10.1530/endoabs.37.ep590

  86. Curtis L, Humayun MA, Walker J, Hampton K. Addition of sglt2 inhibitor to glp1-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. Practical Diabetes 2016;33(4):129-132.

  87. Hayden J, Huang F, McConneell LM, Sainsbury CA. Evaluation of a combination of sglt2 inhibitor and glp1 receptor agonist treatment in type 2 diabetes. Diab Prim Care 2016;18(3).

  88. Saroka RM, Kane MP, Busch RS. Sglt-2 inhibitor therapy added to glp-1 agonist therapy in the management of t2dm. Endocrine Practice 2015;21(12) December.

  89. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011 Oct 27;365(17):1597e604.

  90. Gorgojo-Martinez JJ, Serrano-Moreno C, Sanz-Velasco A, Feo-Ortega G. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist inpatient with type 2 diabetes. Nutr Metab Cardiovasc Dis 2017;27:129-137.

  91. Seino Y, Yabe D, Sasaki T. SGLT2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reduction in Japanese patients with type 2 diabetes: a 52-week , open label, single-arm study. doi: 10.1111/jdi.12694

  92. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.

  93. Frias JP, Guja C, Hardy E, Ahmed A, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION- 8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004-1016.

  94. DeFronzo RA. Effect of combined incretin based therapy plus canagliflozin on glycemic control and the compensatory rise in hepatic glucose production in type 2 diabetic patients. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000.

  95. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Available from: http:// clinicaltrials.gov. NCT02597049.




2020     |     www.medigraphic.com